Abstract
Background:
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
Methods:
Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
Results:
Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
Conclusion:
The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Capecitabine
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Female
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Metastasis / drug therapy
-
Neuroendocrine Tumors / drug therapy*
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Capecitabine
-
Fluorouracil